ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2133

Efficacy of Tocilizumab Therapy in Patients with Rheumatoid Arthritis Based on FDG-PET/CT

Koichi Okamura1, Yukio Yonemoto1, Chisa Okura2 and Kenji Takagishi1, 1Orthopaedic Surgery, Gunma University, Maebashi, Japan, 2Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biologic drugs, Imaging, positron emission tomography (PET), rheumatoid arthritis (RA) and tocilizumab

  • Tweet
  • Email
  • Print
Session Information

Session Title: Imaging of Rheumatic Diseases: Various Imaging Techniques

Session Type: Abstract Submissions (ACR)

Background/Purpose: A humanized anti-interleukin-6 receptor (anti-IL-6R) antibody, tocilizumab (TCZ), is one of the biologics and the C-reactive protein (CRP) level and erythrocyte sedimentation rate (ESR) immediately decrease after the initiation of TCZ therapy. Therefore, it has been proposed that the Disease Activity Score in 28 Joints (DAS28) is an inappropriate marker for assessing the effectiveness of TCZ therapy for RA patients. In fact, clinical physicians are sometimes confused as to how to judge the efficacy of TCZ therapy. Positron emission tomography (PET) with 2-[18F]-fluoro-2-deoxy-D-glucose (18F-FDG) can be used to precisely recognize an increase in synovitis in affected joints, imaging studies with 18F-FDG PET have been performed to assess the metabolic activity of synovitis in RA patients and evaluate the disease activity of RA. Hence, in the present study, we evaluated whether TCZ suppresses synovitis in RA patients after three or six months of treatment and whether conventional assessments of the DAS 28, DAS28-CRP, simplified disease activity index (SDAI) and clinical disease activity index (CDAI) for patients treated with TCZ reflect the improvements in inflammation observed on 18F-FDG PET.

Methods: Seventeen patients (5 males, 12 females; average age: 59.9 ± 11.7 (30-82) years) were enrolled in this study. All patients were diagnosed according to the American College of Rheumatology (ACR) criteria revised in 1987 and had a history of a clinically inadequate response to previous treatment with non-biologic disease modifying antirheumatic drugs (DMARDs), including methotrexate (MTX) and biologic agents, including TNF inhibitors only. 18F-FDG PET was performed at baseline and three and six months after the therapy. The maximum SUV (SUVmax) of the bilateral shoulder, elbow, wrist, hip, knee and ankle joints were totaled (total SUV) and used to assess the degree of FDG uptake as a representative parameter. Wilcoxon’s signed-rank sum test was used to assess differences in the effects of treatment. Spearman’s rank correlation test was applied to test for correlations between the different parameters recorded in this study.

Results: The disease activity scores of the DAS 28, DAS28-CRP, SDAI and CDAI, and total SUV were significantly decreased at three months after the initiation of TCZ. The disease activity and total SUV scores were also found to be further decreased at six months compared to baseline. The ΔSUV, the differences in the total SUV at baseline and three/ six months after treatment, positively correlated with the ΔDAS28 (r = 0.615 p = 0.009/ r = 0.775 p < 0.001), ΔDAS28-CRP (r = 0.696, p = 0.002/ r = 0.828, p < 0.001), ΔSDAI (r = 0.652, p = 0.005/ r = 0.686, p = 0.002) and ΔCDAI (r = 0.662, p = 0.004/ r = 0.711, p = 0.001) for each period.

Conclusion: A reduction in the FDG uptake was observed at three months after the initiation of TCZ therapy. Our results indicate that conventional parameters of TCZ efficacy in RA patients match the disease activity estimated on 18F-FDG PET. 18F-FDG PET can be used to evaluate the response of RA patients to TCZ therapy.


Disclosure:

K. Okamura,
None;

Y. Yonemoto,
None;

C. Okura,
None;

K. Takagishi,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-tocilizumab-therapy-in-patients-with-rheumatoid-arthritis-based-on-fdg-petct/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences